Forkhead BioTherapeutics

Forkhead BioTherapeutics

  • Founded: 2018
  • Location: New York, NY
  • Employee range: 1 - 10
  • Clinical stage: RD
  • Therapy area: Diabetes
  • Drug types: END
  • Lead product: Foxin
  • Product link:
  • Funding: <10M

job board

Short description:

Oral Diabetes Treatment

Drug notes:

Contact us to add description:

Long description:

Forkhead BioTherapeutics is using cellular regeneration to develop novel therapies to treat diabetes. The ability to control blood glucose levels in the body requires cells in the pancreas to secrete insulin. Dysfunction in this system causes diabetes. Forkhead’s approach to treat diabetes involves targeting the cells in the gut and converting some of them to be able to sense blood sugar and secrete insulin. Gut cells are developmentally similar to pancreatic cells and hence are poised to be reprogrammed. To achieve this, Forkhead has developed an oral agent called FoxinTM. FoxinTM inhibits the protein FOXO1 and makes the cells glucose-sensitive and has been shown in preclinical models to be effective.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy